What is HC Wainwright’s Estimate for ZVRA Q1 Earnings?

Zevra Therapeutics, Inc. (NASDAQ:ZVRA) – HC Wainwright issued their Q1 2026 EPS estimates for Zevra Therapeutics in a report released on Tuesday, March 10th. HC Wainwright analyst B. Folkes anticipates that the company will post earnings per share of $0.01 for the quarter. The consensus estimate for Zevra Therapeutics’ current full-year earnings is ($1.95) per share. HC Wainwright also issued estimates for Zevra Therapeutics’ Q2 2026 earnings at $0.03 EPS, Q4 2026 earnings at $0.12 EPS, FY2029 earnings at $2.47 EPS and FY2030 earnings at $2.99 EPS.

ZVRA has been the subject of a number of other research reports. Guggenheim set a $23.00 target price on Zevra Therapeutics and gave the stock a “buy” rating in a research report on Tuesday. Weiss Ratings upgraded Zevra Therapeutics from a “sell (d+)” rating to a “hold (c+)” rating in a research report on Tuesday. Six investment analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company. According to data from MarketBeat, Zevra Therapeutics currently has an average rating of “Moderate Buy” and an average target price of $23.00.

Zevra Therapeutics Stock Down 2.1%

NASDAQ:ZVRA opened at $10.19 on Thursday. The company has a market cap of $598.25 million, a price-to-earnings ratio of 7.66 and a beta of 0.91. The company has a debt-to-equity ratio of 0.40, a quick ratio of 8.57 and a current ratio of 5.68. The stock’s fifty day moving average price is $8.90 and its two-hundred day moving average price is $9.09. Zevra Therapeutics has a 52-week low of $6.19 and a 52-week high of $13.16.

Hedge Funds Weigh In On Zevra Therapeutics

Institutional investors have recently modified their holdings of the stock. Ameritas Investment Partners Inc. increased its position in shares of Zevra Therapeutics by 30.0% in the 2nd quarter. Ameritas Investment Partners Inc. now owns 5,541 shares of the company’s stock valued at $49,000 after buying an additional 1,280 shares in the last quarter. ProShare Advisors LLC lifted its holdings in Zevra Therapeutics by 12.3% during the fourth quarter. ProShare Advisors LLC now owns 12,669 shares of the company’s stock worth $114,000 after acquiring an additional 1,390 shares in the last quarter. The Manufacturers Life Insurance Company grew its stake in Zevra Therapeutics by 9.4% in the second quarter. The Manufacturers Life Insurance Company now owns 20,294 shares of the company’s stock valued at $179,000 after acquiring an additional 1,750 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its stake in Zevra Therapeutics by 6.1% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 31,761 shares of the company’s stock valued at $238,000 after acquiring an additional 1,812 shares during the period. Finally, Deutsche Bank AG increased its holdings in shares of Zevra Therapeutics by 4.4% in the fourth quarter. Deutsche Bank AG now owns 45,939 shares of the company’s stock worth $412,000 after acquiring an additional 1,936 shares in the last quarter. 35.03% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In related news, insider Adrian W. Quartel sold 4,533 shares of the company’s stock in a transaction dated Friday, January 30th. The stock was sold at an average price of $8.83, for a total value of $40,026.39. Following the completion of the sale, the insider owned 9,723 shares in the company, valued at approximately $85,854.09. This represents a 31.80% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, SVP Timothy J. Sangiovanni sold 3,000 shares of the stock in a transaction dated Tuesday, February 3rd. The shares were sold at an average price of $9.18, for a total value of $27,540.00. Following the completion of the transaction, the senior vice president directly owned 29,590 shares in the company, valued at $271,636.20. The trade was a 9.21% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders sold 114,158 shares of company stock worth $1,062,878. Company insiders own 2.40% of the company’s stock.

Key Stories Impacting Zevra Therapeutics

Here are the key news stories impacting Zevra Therapeutics this week:

• Positive Sentiment: HC Wainwright now models Zevra as profitable in FY2026 with FY2026 EPS of $0.23 and quarterly EPS for 2026 (Q1 $0.01, Q2 $0.03, Q3 $0.08, Q4 $0.12) — signaling near‑term profitability expectations that could support valuation if realized. HC Wainwright Estimates (MarketBeat)
• Positive Sentiment: HC Wainwright projects substantial long‑term earnings power — FY2030 EPS of $2.99 — indicating analyst belief in material revenue/profit growth over the next several years if execution meets these assumptions. HC Wainwright Long‑Term Forecasts (MarketBeat)
• Positive Sentiment: Q4 2025 earnings call highlights reportedly pointed to strong revenue growth, a fundamental positive that can support margin expansion and the analyst profitability outlook. Q4 2025 Earnings Call Highlights
• Neutral Sentiment: A Yahoo Finance piece questions whether current pricing already reflects Zevra’s multi‑year share performance — a valuation debate that can increase trading volatility but is not direct company news. Valuation/Price Discussion
• Negative Sentiment: HC Wainwright trimmed several forecasts: FY2026 (to $0.23 from $0.29), FY2027 (to $1.16 from $1.34), FY2028 (to $1.75 from $2.00) and FY2029 (to $2.47 from $2.83). Those downward revisions imply slower growth/earnings ramp than previously modeled and are likely a primary reason for near‑term downward pressure on the stock. Analyst Revisions (MarketBeat)

About Zevra Therapeutics

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy. The company is also developing Celiprolol, a prodrug product candidate that is under Phase 1/2 clinical trial for the treatment of vascular Ehlers Danlos syndrome.